Meglitinide Market Size
| Study Period | 2019- 2029 |
| Market Size (2024) | USD 4.35 Billion |
| Market Size (2029) | USD 4.85 Billion |
| CAGR (2024 - 2029) | 2.21 % |
| Fastest Growing Market | Middle East and Africa |
| Largest Market | Asia-Pacific |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Meglitinide Market Analysis
The Meglitinide Market size is estimated at USD 4.35 billion in 2024, and is expected to reach USD 4.85 billion by 2029, growing at a CAGR of 2.21% during the forecast period (2024-2029).
During the COVID-19 pandemic people with diabetes were more likely to have serious complications from COVID-19. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. Thus, the COVID-19 outbreak increased the meglitinide market's growth globally.
Meglitinides are a class of non-sulfonylurea insulin secretagogues characterized by very rapid onset and shorter duration of action. They stimulate first-phase insulin release in a glucose-sensitive manner, reducing the risk of hypoglycemic events. People with type 2 diabetes have chronically high blood sugar levels and meglitinides make the body free up more insulin.
The World Health Assembly agreed on a Resolution on strengthening the prevention and control of diabetes in may 2021 which recommends action in areas including increasing access to medicines and health products for the treatment of diabetes. According to International Diabetes Federation (IDF), the adult diabetes population in 2021 is approximately 537 million, and this number is going to increase by 643 million in 2030. The rate of newly diagnosed Type 1 and Type 2 diabetes cases is seen to increase, mainly due to obesity, unhealthy diet, and physical inactivity. The rapidly increasing incidence and prevalence of diabetic patients and healthcare expenditure worldwide are indications of the increasing usage of anti-diabetic drugs. Technological advancements and innovations have increased over the period leading to several modifications either in the drugs or the formulations being developed.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Meglitinide Market Trends
Rising diabetes prevalence globally
The diabetes population is expected to rise by 1.92% globally over the forecast period.
The rate of newly diagnosed type-1 and type-2 diabetes cases is seen to increase, mainly due to obesity, an unhealthy diet, and physical inactivity. Increased numbers of people are at increased risk of prediabetes, which can further lead to type-2, causing risk factors for complications, acute and long-term complications, and deaths. The increased prevalence of diabetic patients and healthcare expenditure worldwide are indications of an increased inclination toward diabetic drugs.
Type-2 diabetes is increasingly prevalent and associated with an increased risk for cardiovascular and renal disease. Along with lifestyle changes, meglitinides are oral medications used in the management of type-2 diabetes. They work by lowering blood glucose levels by stimulating insulin release from the beta cells of the pancreas. Their action is dependent upon the presence of functioning beta cells; therefore, meglitinides do not work in people with type-1 diabetes. Technological advancements and innovations have increased over the years, leading to several modifications either in the drugs or the formulations being developed.
WHO launched the Global Diabetes Compact, a global initiative aiming for sustained improvements in diabetes prevention and care, with a particular focus on supporting low and middle-income countries. The Compact is bringing together national governments, UN organizations, nongovernmental organizations, private sector entities, academic institutions, philanthropic foundations, people living with diabetes, and international donors to work on a shared vision of reducing the risk of diabetes and ensuring that all people who are diagnosed with diabetes have access to equitable, comprehensive, affordable, and quality treatment and care.
Therefore, due to increased prevalence and the aforementioned factors, the studied market is anticipated to witness growth over the analysis period.
Middle East and Africa are expected to dominate the Meglitinides Market over the forecast period
Over the forecast period, the Middle East and Africa are expected to register the highest CAGR of about 4%.
Meglitinides act in a similar manner to sulfonylureas. There are currently two meglitinides available: repaglinide and nateglinide. Both are approved for use alone and in combination with other oral diabetes drugs in people with type-2 diabetes. The major effect of meglitinides is the reduction of after-meal blood glucose levels, which results in a reduction in HbA1c. They function by increasing insulin secretion from pancreatic beta cells.
According to IDF 2021, 73 million adults were living with diabetes in the IDF MENA Region in 2021. This figure is estimated to increase to 95 million by 2030. 48 million adults in the IDF MENA Region live with impaired glucose tolerance, which places them at increased risk of developing type-2 diabetes. Diabetes was responsible for 796 thousand deaths in the IDF MENA region in 2021. The Middle East and African regions have witnessed an alarming increase in the prevalence of diabetes. In recent years, the rate of diabetes has reached an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain normal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels.
The government has been working on plans and policies to control the outcome of diabetes. For instance, the Saudi government announced in July 2022 that Saudi Arabia saw growing demand for quality healthcare services spurred by changes including an increasing and aging population and a growing prevalence of lifestyle diseases such as diabetes and obesity. The government and private sector are both involved in working on healthcare entities, certifications, and regulations. The government is taking steps to have 100 percent of Saudi citizens covered by insurance and is working towards ensuring affordability, access, and quality digital healthcare and primary care with cost-effectiveness.
Owing to the aforementioned factors, the market is expected to grow during the forecast period.
Meglitinide Industry Overview
The meglitinide market is fragmented, with manufacturers like Novo Nordisk, Glenmark, and Novartis etc. having a global market presence and the market is highly competitive due to generic drugs manufacturers' presence.
Meglitinide Market Leaders
-
Glenmark Pharmaceuticals
-
Novartis
-
Kissei Pharmaceuticals
-
Biocon
-
Novo Nordisk A/S
*Disclaimer: Major Players sorted in no particular order
Meglitinide Market News
- March 2023: A Randomized, Open-Label, Controlled, Parallel-group, Multicenter Trial was conducted to evaluate the efficacy and safety of INS068 once daily (QD) in subjects with type-2 diabetes not adequately controlled with oral antidiabetic drugs compared to insulin Glargine QD for 26+26 weeks.
- January 2023: OXJournal reviewed the effects of meglitinides as a class of oral medications for treating type 2 diabetes, especially in young adults.
Meglitinide Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Geography
- 5.1.1 North America
- 5.1.1.1 United States
- 5.1.1.2 Canada
- 5.1.1.3 Rest of North America
- 5.1.1.4
- 5.1.2 Europe
- 5.1.2.1 Germany
- 5.1.2.2 Spain
- 5.1.2.3 Italy
- 5.1.2.4 France
- 5.1.2.5 United Kingdom
- 5.1.2.6 Russia
- 5.1.2.7 Rest of Europe
- 5.1.3 Asia-Pacific
- 5.1.3.1 Japan
- 5.1.3.2 China
- 5.1.3.3 Australia
- 5.1.3.4 India
- 5.1.3.5 South Korea
- 5.1.3.6 Malaysia
- 5.1.3.7 Indonesia
- 5.1.3.8 Thailand
- 5.1.3.9 Vietnam
- 5.1.3.10 Philippines
- 5.1.3.11 Rest of Asia-Pacific
- 5.1.4 Latin America
- 5.1.4.1 Brazil
- 5.1.4.2 Mexico
- 5.1.4.3 Rest of Latin America
- 5.1.5 Middle East and Africa
- 5.1.5.1 South Africa
- 5.1.5.2 Saudi Arabia
- 5.1.5.3 Oman
- 5.1.5.4 Egypt
- 5.1.5.5 Iran
- 5.1.5.6 Rest of Middle East and Africa
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Biocon
- 7.1.2 Boehringer Ingelheim
- 7.1.3 Bristol Myers Squibb
- 7.1.4 Glenmark
- 7.1.5 Kissei Pharmaceuticals
- 7.1.6 Mylan
- 7.1.7 Novartis
- 7.1.8 Novo Nordisk
- 7.1.9 Pfizer
- 7.1.10 Teva Pharmaceuticals
- *List Not Exhaustive
-
7.2 MARKET SHARE ANALYSIS
- 7.2.1 Boehringer Ingelheim
- 7.2.2 Novartis
- 7.2.3 Novo Nordisk
- 7.2.4 Other Market Share Analyses
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityMeglitinide Industry Segmentation
Meglitinides, or glinides, are a class of drugs used to treat type-2 diabetes. Meglitinides work by stimulating the pancreas to release insulin in response to a meal. The meglitinide market is segmented by geography (United States, Canada, and the rest of North America). The report offers the value (in USD) and volume (in units) for the above segments. Further, the report will cover a segment-wise breakdown (value and volume) for all the countries covered under the table of contents.
| Geography | North America | United States |
| Canada | ||
| Rest of North America | ||
| Geography | Europe | Germany |
| Spain | ||
| Italy | ||
| France | ||
| United Kingdom | ||
| Russia | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | Japan |
| China | ||
| Australia | ||
| India | ||
| South Korea | ||
| Malaysia | ||
| Indonesia | ||
| Thailand | ||
| Vietnam | ||
| Philippines | ||
| Rest of Asia-Pacific | ||
| Geography | Latin America | Brazil |
| Mexico | ||
| Rest of Latin America | ||
| Geography | Middle East and Africa | South Africa |
| Saudi Arabia | ||
| Oman | ||
| Egypt | ||
| Iran | ||
| Rest of Middle East and Africa |
Meglitinide Market Research FAQs
How big is the Meglitinide Market?
The Meglitinide Market size is expected to reach USD 4.35 billion in 2024 and grow at a CAGR of 2.21% to reach USD 4.85 billion by 2029.
What is the current Meglitinide Market size?
In 2024, the Meglitinide Market size is expected to reach USD 4.35 billion.
Who are the key players in Meglitinide Market?
Glenmark Pharmaceuticals, Novartis, Kissei Pharmaceuticals, Biocon and Novo Nordisk A/S are the major companies operating in the Meglitinide Market.
Which is the fastest growing region in Meglitinide Market?
Middle East and Africa is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Meglitinide Market?
In 2024, the Asia-Pacific accounts for the largest market share in Meglitinide Market.
What years does this Meglitinide Market cover, and what was the market size in 2023?
In 2023, the Meglitinide Market size was estimated at USD 4.25 billion. The report covers the Meglitinide Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Meglitinide Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Meglitinides Industry Report
Statistics for the 2024 Meglitinides market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Meglitinides analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
